

Haematologica  
HAEMATOL/2015/139667  
Version 3

Sepantronium Bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

Sanne J. de Haart, Lisa Holthof, Willy A. Noort, Monique C. Minnema, Maarten E. Emmelot, Tineke Aarts-Riemens, Parul Doshi, Kate Sasser, Huipin Yuan, Joost de Bruijn, Anton C.M. Martens, Niels W.C.J. van de Donk, Henk M. Lokhorst, Richard W.J. Groen, and Tuna Mutis

Disclosures: This work was funded by Janssen Pharmaceuticals, USA HML, NvD, AM en TM have received research support from Janssen Pharmaceuticals, USA, PD and AKS are employees of Janssen Pharmaceuticals, USA. HML and NvD also received research support from Celgene. Other authors have no disclosures.

Contributions: SJH, LH, TA-R executed, analyzed and interpreted the in vitro experiments; SH, RG, WN ME, ACM executed analyzed and interpreted the in vivo experiments; PD, AKS provided essential reagents, interpreted data and edited the manuscript; MCM, NvdD, HL and TM designed the study, analysed the data, interpreted the results and edited the manuscript. SH wrote the first draft, TM wrote the final draft of the manuscript.